Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: Provided are a storage method and a banking system of cells prepared using somatic cell nuclear transfer (NT) technology with homozygous genotypes of genes of human leukocyte antigen (HLA)-A, HLA-B, HLA-DR, and the like. The banking of NT cell-derived stem cells may be applied to autologous or allogenic patients and can provide transplantable cells and tissue materials for the treatment of various diseases such as diabetes, osteoarthritis, Parkinson's disease, and the like.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: A solar panel frame waterproof structure, comprising multiple solar panels (1), multiple frames (2), multiple frame bodies (3), and multiple sealing strips (4).

Abstract: A stabilized aPGF composition or a method for stabilization of the pharmaceutical composition comprising aFGF are provided. The composition comprises aPGF, a citric acid compound and other excipients. The method for improving stability of aPGF in the form of a liquid formulation or a lyophilized formulation so as to increase storage stability is also provided.

Abstract: The present invention discloses the inhibitory effect of azvudine as an immunomodulator on mice bearing CT-26 tumor. It is found that azvudine has no significant anti-tumor effect on immunodeficient B-NDG mice bearing CT-26 tumor, yet has an antitumor effect on BALB/c mice with normal immunity bearing CT-26 tumor model. The present invention further studies the combined effect of azvudine and PD-1 antibody, and finds that compared with a single drug, the combined administration has a synergistic anti-tumor effect.

Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.

Abstract: Disclosed is a monoclonal antibody that specifically binds BCMA, or an antigen binding fragment thereof, and its use in treating cancers such as multiple myeloma. Also disclosed is a monoclonal antibody that specifically binds CD3, or an antigen binding fragment thereof, and its use in treating or alleviating an inflammatory disease, an autoimmune disease, or transplantation rejection. Further disclosed is an anti-BCMA/CD3 bispecific antibody, and its use in treating diseases such as cancers.

Abstract: The present invention discloses a pharmaceutical composition comprising azvudine and a chemotherapeutic agent. The pharmaceutical composition of the present invention shows a good synergistic effect in antitumor, and can reduce the dosage of chemotherapeutic agent, and improve the therapeutic effect and safety, thereby achieving the goal of prolonging the survival of patients.

Abstract: Provided is a method for introducing a point mutation to a BBD29_04920 gene coding sequence in Corynebacterium or improving the expression thereof. The point mutation causes a mutation to the base at position 1560 in the BBD29_04920 gene sequence from cytosine (C) to adenine (A) such that asparagine at position 520 of a coded corresponding amino acid sequence is substituted by lysine. The method can increase fermentation yield of glutamic acid in a strain with the mutation. Also provided are the bacterium generating L-glutamic acid, a nucleic acid and protein comprising the mutation, a recombinant vector and recombinant strain comprising the nucleic acid, and use of these biomaterials in the regulation of the production of L-glutamic acid of a microorganism.

Abstract: A bispecific fusion protein may include a first binding domain and a second binding domain. The first binding domain may include an antibody specifically binding to PD-L1, the antibody may include two antibody light chains and two antibody heavy chains, and the antibody light chains and the antibody heavy chains may be linked by disulfide bonds. The second binding domain may include an Ig-like domain of VEGFR1 and an Ig-like domain of VEGFR2. The N-terminus of the Ig-like domain of VEGFR1 or the N-terminus of the Ig-like domain of VEGFR2 may be directly or indirectly linked to the C-terminus of the antibody heavy chains, separately. A pharmaceutical composition may include the bispecific fusion protein. Such a bispecific fusion protein may be pharmaceutically used and may effectively and safely kill tumor cells.

Abstract: A hydrophilized ePTFE sheet includes an ePTFE sheet, Japanese paper laminated on the surface of the ePTFE sheet processed with an atmospheric pressure plasma treatment, and a collagen layer applied to the surface of the Japanese paper.

Abstract: Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from glutathione and a derivative thereof, and the derivative of glutathione is selected from: at least one of amino or carboxyl in glutathione substituted with an amino protecting group and/or a carboxyl protecting group; B is a monovalent or divalent balance anion; and n is 1 or 2.

Abstract: A method for catalytically synthesizing furaneol, which uses a specific peptide to function as a catalyst, uses rhamnose to function as a raw material, and uses an organic solvent and a phosphate buffer to function as a reaction solvent to be co-heated to prepare furaneol.

Abstract: The present invention relates to the field of biotechnologies. Disclosed are an enzyme composition for preparing ?-nicotinamide mononucleotide (NMN), and an application thereof. In the present invention, by using adenosine and nicotinamide as raw materials, D-ribose 1-phosphate and a nicotinamide ribose intermediate are generated under enzyme catalysis of an enzyme composition of a PNP enzyme and an NRK enzyme, and finally NMN is obtained; only two enzymes need to be involved in the whole reaction system, and the by-product adenine can be recycled. Moreover, only one molecule of ATP needs to be consumed for generating one molecule of NMN, thereby greatly reducing the process cost. The reaction of synthesizing NMN by NRK enzyme catalysis in the last step is irreversible, and thus, the substrate conversion rate can be greatly improved and the production cost can be further reduced.

Abstract: The present disclosure belongs to the technical field of coenzyme Q10, and relates to a coenzyme Q10 oiling agent, a preparation method and a use thereof. The coenzyme Q10 oiling agent comprises the following components in percentage by mass: 20-40% of coenzyme Q10, 45-65% of mixed oil, 10-15% of biphase emulsifying agent, wherein the coenzyme Q10 in the coenzyme Q10 oiling agent is present in a molecular form above 0° C.; the mixed oil simultaneously contains a saturated fatty acid (ester) and an unsaturated fatty acid (ester); the biphase emulsifying agent simultaneously contains a hydrophilic emulsifying agent and a lipophilic emulsifying agent. The coenzyme Q10 in the coenzyme Q10 oiling agent provided by the present disclosure still can be stably present in the molecular form at high content, and therefore has high bioavailability.